{
    "nct_id": "NCT06428500",
    "official_title": "A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of QTX3046 in Patients with Advanced Solid Tumors with KRAS G12D Mutations",
    "inclusion_criteria": "* Pathologically documented, locally advanced or metastatic malignancy with KRAS G12D mutations identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic.\n* Part 1: Advanced solid tumors with at least one prior systemic therapy.\n* Evaluable and measurable disease per RECIST v1.1.\n* Part 2 and 3: Measurable disease per RECIST v1.1\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain metastasis or carcinomatous meningitis\n* Significant cardiovascular disease\n* Active infection requiring intravenous (IV) antibiotics\n* Prior treatment with a KRAS inhibitor\n\nOther protocol-defined Inclusion/Exclusion Criteria may apply",
    "miscellaneous_criteria": ""
}